Ultragenyx Pharma (RARE) Misses Q2 EPS by 51c; Reaffirms Product Revenue Guidance

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.26), $0.51 worse than the analyst estimate of ($1.75). Revenue for the quarter came in at $89.3 million versus the consensus estimate of $87.65 million.

GUIDANCE:

Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• AeroVironment restates quarterly financials, citing $89M goodwill error